Anifrolumab Reduces Renal Inflammation Markers in Lupus Nephritis: Phase 2 Trial
USA: Researchers have found in a new study that treatment with Anifrolumab significantly reduced urinary biomarkers of renal histologic activity in patients with Lupus Nephritis compared with placebo. These findings suggest the therapy may accelerate the resolution of intrarenal inflammation and potentially help prevent long-term kidney damage.
Lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), is driven in part by dysregulated type I interferon pathways. Targeting this pathway, anifrolumab—already approved for SLE—has been evaluated for its potential benefits in LN. In a recent Phase 2 randomized trial (TULIP-LN), researchers led by Andrea Fava from the Johns Hopkins University School of Medicine examined how this therapy affects urinary biomarkers associated with kidney inflammation.
The study included patients receiving standard therapy alongside either anifrolumab (basic or intensified regimens) or placebo. Urine samples collected at baseline, week 12, and week 48 were analyzed using proteomic techniques to measure 197 proteins associated with renal inflammation and histologic activity.
The trial revealed the following findings:
- Anifrolumab significantly reduced key urinary inflammatory biomarkers, including CD163 and monocyte chemoattractant protein-1, as early as week 12 compared to placebo.
- This reduction was observed even in patients without improvement in proteinuria, suggesting benefits beyond conventional clinical measures.
- By week 48, biomarker levels declined across all groups, including those receiving placebo with standard therapy.
- Standard therapy alone can reduce intrarenal inflammation over time, but anifrolumab accelerates this process, leading to earlier immunologic improvement.
- Proteomic analysis showed that anifrolumab more effectively suppressed the overall inflammatory protein signature compared to placebo.
- The reduction in inflammatory markers occurred irrespective of clinical response status.
- These findings indicate that molecular improvements in kidney inflammation may occur independently of traditional indicators such as proteinuria.
The study provides important insights into the dynamics of immune modulation in LN. According to the researchers, anifrolumab may trigger earlier and potentially more meaningful changes in kidney inflammation than can be captured by routine clinical endpoints alone. This could have implications for improving long-term renal outcomes if such early changes translate into sustained disease control.
However, the authors caution that the findings should be interpreted in light of certain limitations. The relatively small sample size limits the statistical strength of the conclusions. Additionally, the absence of long-term renal outcome data makes it difficult to determine whether the observed biomarker improvements will lead to meaningful clinical benefits. The lack of follow-up kidney biopsies also restricts the ability to directly correlate changes in urinary biomarkers with histological improvement in kidney tissue.
Overall, the analysis from the TULIP-LN trial, published in Arthritis & Rheumatology, suggests that anifrolumab may offer a promising approach to more rapidly control kidney inflammation in lupus nephritis, potentially reducing the risk of chronic kidney damage.
Reference:
Fava, A., Petri, M., Gavin, P. G., Csomor, E., Brohawn, P. Z., Muthas, D., Platt, A., Lindholm, C., & Ferrari, N. Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.70089
Next Story